A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Yale University
Medical College of Wisconsin
Baylor Research Institute
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
NRG Oncology
Mayo Clinic
Bold Therapeutics, Inc.
National Health Research Institutes, Taiwan
IMGT Co., Ltd.
Medical College of Wisconsin
National Health Research Institutes, Taiwan
Taiho Oncology, Inc.